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Recommendations for head and neck surgical oncology
practice in a setting of acute severe resource constraint
during the COVID-19 pandemic: an international consensus
Hisham Mehanna*, John C Hardman*, Jared A Shenson*, Ahmad K Abou-Foul*, Michael C Topf*, Mohammad AlFalasi, Jason Y K Chan,
Pankaj Chaturvedi, Velda Ling Yu Chow, Andreas Dietz, Johannes J Fagan, Christian Godballe, Wojciech Golusiński, Akihiro Homma, Sefik Hosal,
N Gopalakrishna Iyer, Cyrus Kerawala, Yoon Woo Koh, Anna Konney, Luiz P Kowalski, Dennis Kraus, Moni A Kuriakose, Efthymios Kyrodimos,
Stephen Y Lai, C Rene Leemans, Paul Lennon, Lisa Licitra, Pei-Jen Lou, Bernard Lyons, Haitham Mirghani, Anthony C Nichols, Vinidh Paleri,
Benedict J Panizza, Pablo Parente Arias, Mihir R Patel, Cesare Piazza, Danny Rischin, Alvaro Sanabria, Robert P Takes, David J Thomson,
Ravindra Uppaluri, Yu Wang, Sue S Yom, Yi-ming Zhu, Sandro V Porceddu†, John R de Almeida†, Chrisian Simon†, F Christopher Holsinger†

The speed and scale of the global COVID-19 pandemic has resulted in unprecedented pressures on health services
worldwide, requiring new methods of service delivery during the health crisis. In the setting of severe resource
constraint and high risk of infection to patients and clinicians, there is an urgent need to identify consensus
statements on head and neck surgical oncology practice. We completed a modified Delphi consensus process of
three rounds with 40 international experts in head and neck cancer surgical, radiation, and medical oncology,
representing 35 international professional societies and national clinical trial groups. Endorsed by 39 societies and
professional bodies, these consensus practice recommendations aim to decrease inconsistency of practice, reduce
uncertainty in care, and provide reassurance for clinicians worldwide for head and neck surgical oncology in the
context of the COVID-19 pandemic and in the setting of acute severe resource constraint and high risk of infection to
patients and staff.

Introduction
WHO declared the COVID-19 outbreak to be a global
pandemic on March 11, 2020.1 The speed and scale of the
spread of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has resulted in unprecedented pressures
on health services worldwide.2–4 The need for hospital
isation and mechanical ventilation in intensive care for a
considerable proportion of patients, in addition to staff
shortages due to illness and concerns of viral trans
mission to health-care workers and other patients, have
led to a severe curtailment of health-care capacity and
resources.5–8 System constraints preventing the delivery
of timely and comprehensive care, the fear of viral
transmission, and poor clinical outcomes of patients
with head and neck cancer developing COVID-19 during
the perioperative period have greatly impacted surgical
practice and decision making in this cancer setting.9–14
Many clinical services have had to substantially reduce,
or even cease, their routine clinical activity.15–17 Further
more, services have had to adapt by adopting new
strategies for care delivery, with the aim of releasing
capacity and reducing the risk of nosocomial infection to
patients and staff due to travel and face-to-face contact in
hospital.18,19
In the setting of the COVID-19 pandemic, adherence to
previously established standards of care have proven
difficult.20 Patient evaluation (including use of flexible
nasendoscopy and diagnostic imaging), achieving target
wait times for surgery, and oncological surveillance
have all been affected.21 In this climate of constrained
resources, consideration should be given to prioritisation
of surgical cases and innovative methods of patient
evaluation and surveillance.14 Individual institutions and
www.thelancet.com/oncology Vol 21 July 2020

national professional organisations have produced
guidelines and clinical protocols during the pandemic.22–27
By necessity, such guidelines have been developed
hastily, usually by individuals or small groups of
clinicians, and have often not been subjected to the usual
processes of peer review that were implemented before
the COVID-19 pandemic. As a result, there has been
some confusion among head and neck cancer surgeons
as to which advice should be followed.
The Head and Neck Cancer International Group
(HNCIG), a collaboration of 20 national clinical trial
groups for head and neck cancer across three continents,
identified an urgent need for consensus practice
recommendations for head and neck surgical oncology
that could be applied globally in the setting of severely
constrained resources. To address this need, we rapidly
developed expert consensus recommendations for the
management of surgical patients with head and neck
cancer during the COVID-19 pandemic using a modified
online Delphi process with representation from the
relevant multidisciplinary bodies worldwide.

Data collection

Participant selection
In total, 35 international and national head and neck
oncology organisations were invited to participate by
the steering committee, which was composed of the
members of the HNCIG Surgical Committee. The
invited organisations included all 20 clinical trial groups
of the HNCIG, who were invited to nominate a surgical
representative to be part of the consensus panel.
Member groups were the Canadian Cancer Trials
Group, Cancer Trials Ireland, the Danish Head and
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Germany (Prof A Dietz PhD);
Division of Otolaryngology,
University of Cape Town,
Cape Town, South Africa
(Prof J J Fagan MBChB);
Department of
Otorhinolaryngology–Head
and Neck Surgery, Odense
University Hospital and
University of Southern
Denmark, Odense, Denmark
(Prof C Godballe PhD);
Department of Head and Neck
Surgery, Poznan University of
Medical Sciences, Greater
Poland Cancer Centre, Poznan,
Poland (Prof W Golusiński PhD);
Department of
Otolaryngology–Head and
Neck Surgery, Faculty of
Medicine and Graduate School
of Medicine, Hokkaido
University, Sapporo, Japan
(Prof A Homma PhD);
Department of
Otolaryngology–Head and
Neck Surgery, Atilim University
Faculty of Medicine, Ankara,
Turkey (Prof S Hosal MD);
Department of Head and Neck
Surgery, National Cancer
Centre and Singapore General
Hospital, Singapore
(Prof N G Iyer MD); Department
of Otorhinolaryngology, Yonsei
University, Seoul, South Korea
(Prof Y W Koh PhD); Department
of Otolaryngology, Komfo
Anokye Teaching Hospital,
Kwame Nkrumah University of
Science and Technology, School
of Medical Science, Kumasi,
Ghana (A Konney MD);
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Surgery, University of
Sao Paulo Medical School,
Sao Paulo, Brazil
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Sao Paulo, Brazil
(Prof L P Kowalski); Department
of Otolaryngology–Head and
Neck Surgery, Zucker School of
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Neck Cancer Group, the Dutch Head and Neck Society,
the Eastern Cooperative Oncology Group and the
American College of Radiology Imaging Network, the
European Organisation for Research and Treatment of
Cancer, the French Head and Neck Cancer Group,
Fudan University Shanghai Cancer Center, the German
Interdisciplinary Working Group for Head and Neck
Tumors, the Hellenic Cooperative Oncology Group,
Hong Kong Nasopharyngeal Carcinoma Study Group,
the Japanese Clinical Oncology Group and The Head
and Neck Cancer Study Group, the National Cancer
Centre Singapore, the National Cancer Research
Institute UK, the North West Italian Oncology Group,
NRG Oncology-Head and Neck Cancer Committee, the
Spanish Head and Neck Cancer Cooperative Group,
Taiwan Cooper
ative Oncology Group, Tata Memorial
Centre, and Trans-Tasman Radiation Oncology Group.
To ensure adequate representation from all continents
and geographical regions, the following international
and national head and neck surgical societies were
also invited to nominate surgical representatives: the
European Head and Neck Society, the African Head and
Neck Society, the Latin American Cooperative Oncology
Group, the International Committee of the American
Head and Neck Society, the International Federation of
Head and Neck Oncological Societies, the International
Association of Oral Oncology, the Korean Society of Head
and Neck Surgery, the National Cancer Centre–Chinese
Academy of Medical Sciences and Peking Union Medical
College Cancer Hospital, the United Arab Emirates
Otorhinolaryngological and Head and Neck Society
(Middle East), the British Association of Head and Neck
Oncologists, the Head and Neck Cancer Society of
Turkey, and the Australian and New Zealand Head and
Neck Cancer Society.
To ensure multidisciplinary representation, the following
international organisations were also invited to nominate
medical and radiation oncologists: the American Society of
Clinical Oncology, the American Society for Radiation
Oncology, and the European Society for Radiotherapy
and Oncology. These leading radiotherapy and medical
oncology societies all have global membership.
All invited organisations agreed to participate and each
organisation’s governing executive made their respective
nomination. Nominees had to be currently practising as
a head and neck cancer clinician, considered to be a
national or international expert, and be willing to
complete all three rounds of the online Delphi process
within 14 days. All partici
pants were included in the
manuscript authorship.

Consensus formation
To achieve consensus, an online modified Delphi process
was done over three rounds. Nominated experts were
invited to complete an anonymous online questionnaire,
delivered by the Qualtrics online survey platform
(Qualtrics, Salt Lake City, UT, USA). The survey included

three main sections: clinical protocols, treatment
protocols, and prioritisation of treatment, all within the
context of severe resource constraint and risk of
transmission caused by the prevalence of SARS-CoV-2 in
the patient population. An overview of the modified
Delphi process is shown in the figure.
Participants were invited by email to complete each
round of the survey, which was open for a period of 24 h.
A reminder email was sent at 2 h and 1 h before the
deadline to prompt participants who had not yet
completed their responses.
When making their recommendations, participants
were instructed to consider an extremely constrained
setting in terms of capacity and resources (including a
severe reduction in staffing, operating room capacity,
inpatient and intensive care bed capacity) compared with
baseline before the COVID-19 pandemic.
After each round, data were analysed by the multi
disciplinary steering group and predetermined criteria for
agreement were applied. These criteria were set a priori in
the protocol before the start of the project and were
extrapolated from the RAND method.28 A threshold of 80%
and above was used to signify strong agreement for a
statement; whereas, 20% and below indicated strong
disagreement. For each statement, the Delphi process was
stopped either when strong agreement was reached or
after completion of three rounds, whichever occurred first.
Items that reached strong agreement were dropped from
subsequent rounds. Additionally, after the third round,
statements that did not reach the strong agreement
threshold but reached a threshold of 67% and over were
considered to have reached agreement.13
Results from the first and second rounds were emailed
to participants to allow them to be reviewed before
the next round opened. Participants were repeatedly
reminded that they could change their responses in
the subsequent round for questions that had not yet
reached strong agreement. Results from the first and
second rounds were also presented immediately above
the relevant question on Qualtrics. When necessary,
questions were iteratively revised between rounds before
being repiloted, and a few new questions were introduced
to provide more granularity to the topic or to reduce
ambiguity on the phrasing of a previous question. The
resulting recommendations were then circulated to the
partici
pating bodies and societies for endorsement.
Furthermore, we received requests from other profes
sional bodies of head and neck surgical oncology to
endorse the recommendations.
The project was given a waiver by the Research Ethics
Department at the University of Birmingham
(Birmingham, UK) and by the Institutional Review Board
at Stanford University (Paolo Alto, CA, USA).

Findings
Invitations were sent to 40 nominees representing
35 societies and groups. These nominees included
www.thelancet.com/oncology Vol 21 July 2020
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Delphi survey
preparation

Round 1

Topics and response items prepared
Input from: literature search, head and neck cancer communications, HNCIG board members

Online survey data collection
78 items evaluated
40 of 40 (100%) experts participated

30 items reached
consensus

Survey piloted by external experts and
feedback incorporated

Six items
modified for
clarity

Nine items
added

Results analysed by steering committee
Revised survey piloted by external experts

Round 2

First round results distributed to participants via email and
embedded in second round online survey

42 items reached
consensus

Online survey data collection
81 items evaluated
40 of 40 (100%) experts participated

Two items
modified for
clarity

No items added

Revised survey piloted by external experts
Results analysed by steering committee

Round 3

Second round results distributed to participants via email
and embedded in third round online survey
13 items reached
consensus
Online survey data collection
41 items evaluated
40 of 40 (100%) experts participated

Results analysed by steering committee

18 items did not
reach consensus

+72 items reaching
consensus in rounds 1 and 2
Delphi consensus recommendations prepared by steering
committee and endorsed by 39 professional societies and groups

Figure: HNCIG modified Delphi process
HNCIG=Head and Neck Cancer International Group.

33 surgeons, three radiation oncologists, two medical
oncologists, and two maxillofacial surgeons. The full list
is provided in the appendix (p 1). All 40 experts
participated in each of the three rounds of the survey,
with no dropouts or substitutions between rounds. The
recom
mendations were endorsed by 39 societies and
professional bodies (panel 1).
In total, 78 questions were asked in the first round
with an average completion time of 80·0 min,
81 questions in the second round with an average
completion time of 33·2 min, and 41 questions in the
third round with an average completion time of
19·3 min.
The rates of agreement reported reflect when the item
first reached one of the agreement thresholds that were
outlined in the data collection section. These rates
might have been after one, two, or three rounds of
www.thelancet.com/oncology Vol 21 July 2020

questioning. Full results of each round are provided in
the appendix (pp 2–5).

Clinical protocols and procedures
A summary of the consensus findings for clinical
management is available in table 1. Experts reached a
strong agreement that flexible nasendoscopy is appro
priate only if adequate personal protection equipment
(PPE) is available for clinicians in patients with either
symptoms or examination findings suggestive of a new
primary head and neck cancer or recurrence (92·5%),
and in patients with concern for critical airway
obstruction (97·5%).
Experts also reached strong agreement (80·0%) that
flexible nasendoscopy is not appropriate in patients with
no history of head and neck cancer who present with lowrisk symptoms (eg, globus pharyngeus). In asymptomatic
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Panel 1: Bodies and societies endorsing the recommendations
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Head and Neck Cancer International Group
African Head and Neck Society
American Society for Radiation Oncology
Associazione Italiana Oncologia Cervico-Cefalica
Australian and New Zealand Head and Neck Cancer Society
Australian Society of Otolaryngology
British Association of Head and Neck Oncologists
Canadian Cancer Trials Group
Cancer Trials Ireland
Danish Head and Neck Cancer Group
Dutch Head and Neck Society
European Head and Neck Society
European Organization for Research and Treatment of Cancer
European Society for Radiotherapy and Oncology
French Head and Neck Cancer Group
German Interdisciplinary Working Group for Head and Neck Tumors
Head and Neck Cancer Society, Singapore
Head and Neck Cancer Society of Turkey
Head and Neck Cancer Study Group of the Japan Clinical Oncology Group
Hellenic Cooperative Oncology Group
Korean Society of Head and Neck Surgery
Hong Kong Nasopharyngeal Carcinoma Study Group
Hong Kong Head and Neck Society
International Committee of the American Head and Neck Society
International Federation of Head and Neck Oncological Societies
Latin American Clinical Oncology Group
National Cancer Center–Chinese Academy of Medical Sciences and Peking Union
Medical College Cancer Hospital
National Cancer Centre Singapore
UK National Cancer Research Institute Head and Neck Group
North West Italian Oncology Group
NRG Oncology Head and Neck Cancer Committee
Spanish Head and Neck Cancer Cooperative Group
Spanish Otorhinolaryngology and Head and Neck Surgery Society
Spanish Oral, Maxillofacial and Head and Neck Surgery Society
Taiwan Cooperative Oncology Group
Taiwan Head and Neck Society
Tata Medical Center
Trans-Tasman Radiation Oncology Group
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Oncology, University of
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Australia (Prof D Rischin MD);
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Center, Nijmegen, Netherlands
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patients with a previous history of head and neck cancer
attending clinic for routine follow-up, there was strong
agreement (97·5%) that flexible nasendoscopy is not
appropriate without adequate PPE. However, experts
could not agree on whether flexible nasendoscopy in these
patients is appropriate if PPE is available. A majority of
respondents (60·0%) believed that it was not appropriate
to use flexible nasendoscopy at all in this cohort.
When confirming a diagnosis of head and neck cancer,
there was strong agreement (92·5%) that a positive
cytohistological result from fine needle aspiration or core
biopsy of a suspicious node and suspicious imaging
together are acceptable confirmations of a cancer dia
gnosis, even in the absence of a biopsy of the primary

tumour site. There was also strong agreement that
suspicious findings on CT or MRI (80·0%), or PET-CT
(82·5%) scans alone, are not acceptable to confirm a
cancer diagnosis.
There was also strong agreement (85·0%) that if a
tumour can be biopsied under local anaesthesia, then a
full panendoscopy (laryngoscopy, hypo
phar
yngoscopy,
and upper oesophagoscopy) under general anaesthesia is
not required. However, if general anaesthesia is needed to
biopsy the tumour, there was agreement (67·5%) that a
full panendoscopy should be done at the same time.
In routine patients with head and neck cancer
3 months or more after surgery, there was strong
agreement (80·0%) on monitoring follow-up through
video or phone consultations, with face-to-face review
only in the case of suspicious findings. There was also
agreement (70·0%) that it is appropriate to combine
routine face-to-face and video or phone consultations.
However, there was no agreement (47·5%) that video
or phone consultations alone is an appropriate method
of follow-up for these patients. There was strong
agreement (100·0%) that it is not appropriate to stop
follow-up altogether. There was also agreement (67·5%)
that the normal frequency of follow-up should be
maintained.
There was strong agreement (100·0%) that the
COVID-19 status of a patient should be considered before
surgery. To make a positive diagnosis of COVID-19, there
was strong agreement (80·0%) that a positive laboratory
test alone would be sufficient as the minimum criterion.
There was also agreement (72·5%) that a positive clinical
history and a positive laboratory test together are
acceptable minimum criteria. Furthermore, experts
agreed (70·0%) that it is not sufficient to use a positive
clinical history (including symptoms) alone to make a
COVID-19 diagnosis, and strongly agreed (100·0%) that
positive chest imaging alone is also not sufficient for
diagnosis. There was no agreement regarding use of
positive clinical history and positive imaging together
(57·5%) or use of clinical history, positive laboratory test,
and positive imaging altogether (52·5%) as the minimum
criteria for a diagnosis of COVID-19.
When operating on a patient with confirmed or highly
suspected COVID-19 and who does not have indications
for emergency intervention (eg, no impending airway
obstruction), there was strong agreement (95·0%) that
the operation should be postponed until both the
patient’s symptoms resolve and a negative COVID-19
result is obtained on repeat laboratory testing.

Treatment protocols
Early head and neck cancer
In the case of an early T1–T2 N0 oral cancer, there was
strong consensus (95·0%) that it is not acceptable to
delay surgery for more than 8 weeks from diagnosis.
Among this group of respondents, 47·5% would not
accept delaying surgery for more than 4 weeks from
www.thelancet.com/oncology Vol 21 July 2020
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diagnosis; whereas, 55·0% would accept delaying
surgery for up to 8 weeks. There was also strong agree
ment (100·0%) against palliation as primary treatment
in the setting of anticipated delay to surgery. If delay
to surgery is anticipated to be between 4 weeks and
8 weeks, there was strong agreement that immediate
treat
ment with alternative therapies to surgery (eg,
therapy) was not acceptable (82·5%), and that
radio
serial monitoring is acceptable (87·5%), with consider
ation of surgery or alternative therapies if the tumour
progresses clinically significantly. If surgery is not anti
cipated to occur within 8 weeks, there was preferential
agreement (67·5%) to use serial monitoring, with no
agreement (45·0%) on treating with primary radio
therapy in such a case.
In the case of an early T1 N0 laryngeal cancer, there
was agreement (72·5%) that surgery could be delayed
for more than 4 weeks, but only 47·5% of respondents
agreed that surgery could be delayed for up to 8 weeks.
There was strong agreement (92·5%) not to delay
surgery beyond 8 weeks. There was agreement (70·0%)
that it is acceptable to treat immediately with radio
therapy as an alternative to surgery. If a delay to surgery
of 4–8 weeks is anticipated, there was agreement (67·5%)
that radiotherapy should be recommended immediately
instead of surgery; whereas, if a delay of more than
8 weeks is anticipated, there was strong agreement
(92·5%) that radiotherapy should be recommended
immediately over surgery. There was agreement (75·0%)
that serial monitoring should not be used and strong
agreement (100%) that palliative treatment as the only
treatment was not appropriate in this setting.

Advanced head and neck cancer
In the case of an advanced head and neck cancer that
would require extended operative time and extended
hospital stay, intensive care, or both (eg, T4 N1 laryngeal
cancer, N2b oral cancer, or a patient requiring bone
resection such as maxillectomy), there was strong
agreement (87·5%) that it is not acceptable to delay
surgery beyond 4 weeks of diagnosis, as per previous
standards of care. If surgery could not occur within this
timeframe, there was strong agreement (90%) that
alternative treatment such as radiotherapy or chemo
radiotherapy should be given immediately. There was no
consensus regarding the provision of induction (metro
nomic) chemotherapy until surgery is possible, with only
50·0% of respondents supporting this form of treatment
if surgery is not anticipated within an acceptable time
frame. There was strong agreement (86·2%) against use
of serial monitoring or palliation as the only treatment in
these situations.

Differentiated thyroid cancer
In the case of a differentiated thyroid cancer (eg, T1–T3
or N0–N1b) with no adverse features (no extension into
strap muscles, trachea or oesophageal musculature, no
www.thelancet.com/oncology Vol 21 July 2020

Agreement level
Clinical and diagnostic procedures
Use of flexible nasendoscopy
For patients with symptoms or signs suggestive of a new primary cancer or
recurrence: use flexible nasendoscopy only if adequate PPE is available and do
not use flexible nasendoscopy in absence of adequate PPE

Strong agreement

For patients with concern for critical airway obstruction: use flexible
nasendoscopy only if adequate PPE is available and no not use flexible
nasendoscopy in absence of adequate PPE

Strong agreement

For asymptomatic patients with a previous history of head and neck cancer
attending clinic for routine follow-up: do not use flexible nasendoscopy in
absence of adequate PPE

Strong agreement

For patients with no history of head and neck cancer presenting with low-risk
symptoms (eg, globus pharyngeus): do not use flexible nasendoscopy

Strong agreement

To confirm a diagnosis of head and neck cancer
Positive fine needle aspiration or core biopsy of a suspicious lymph node and
suspicious imaging together are acceptable

Strong agreement

Suspicious findings on imaging, whether CT, MRI, or PET-CT scans alone,
without biopsy, are not acceptable

Strong agreement

If a biopsy under local anaesthesia can be done, no panendoscopy is needed

Strong agreement

If a biopsy under general anaesthesia is needed, a full panendoscopy should be
done at the same time

Agreement

Follow-up of patients with head and neck cancer ≥3 months after surgery
Use video or phone consultations, with face-to-face reviews only in the case of
suspicious findings

Strong agreement

Use a combination of routine scheduled face-to-face and video or phone
consultations

Agreement

Do not stop follow-up completely

Strong agreement

Maintain the normal frequency of follow-up

Agreement

Minimum criteria required for diagnosing a patient with COVID-19 before head and neck cancer surgery
COVID-19 status should be considered before surgery

Strong agreement

Positive laboratory test alone is sufficient

Strong agreement

Positive clinical history and positive laboratory test together are sufficient

Agreement

Positive clinical history (including symptoms) alone is not sufficient

Agreement

Positive chest imaging alone is not sufficient

Strong agreement

Delay of surgery in patients with confirmed or highly suspected COVID-19, with no indication for emergency
intervention
Delay operation until patient symptoms resolve and negative COVID-19 repeat
laboratory testing

Strong agreement

Treatment protocols
For T1–T2 N0 oral cancer
Operate within 8 weeks from diagnosis

Strong agreement

Do not delay surgery for up to 12 weeks from diagnosis

Strong agreement

If surgery delay of 4–8 weeks is anticipated, do not treat immediately with
alternative treatments such as radiotherapy

Strong agreement

If surgery delay of 4–8 weeks is anticipated, use serial monitoring with surgery
or alternative treatment (eg, radiotherapy) only if tumour progresses clinically
significantly

Strong agreement

If surgery delay of >8 weeks is anticipated, use serial monitoring, with surgery or Agreement
alternative treatment (eg, radiotherapy) only if tumour progresses clinically
significantly
If surgery delay of any duration is anticipated, do not treat with palliation as
primary treatment

Strong agreement

For early T1 N0 laryngeal cancer
Can delay surgery for >4 weeks, if necessary

Agreement

Do not delay surgery beyond 8 weeks

Strong agreement

Treat immediately with radiotherapy as an alternative to surgery

Agreement
(Table 1 continues on next page)
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Agreement level
(Continued from previous page)
If surgery delay of 4–8 weeks is anticipated, recommend radiotherapy
immediately instead of surgery

Agreement

If surgery delay of >8 weeks is anticipated, recommend radiotherapy
immediately instead of surgery

Strong agreement

Do not use serial monitoring with treatment only if tumour progresses

Agreement

Do not treat with palliation as primary treatment

Strong agreement

For advanced head and neck cancer
Do not delay surgery; operate within 4 weeks of diagnosis

Strong agreement

Do not use serial monitoring or give palliation as only treatment

Strong agreement

Give alternative treatment (eg, radiotherapy or chemoradiation) immediately if
surgery cannot occur within 4 weeks

Strong agreement

For differentiated thyroid cancer (T1–T3 or N0–N1b) with no adverse features
Can delay surgery for up to 12 weeks from diagnosis, if necessary

Strong agreement

Do not delay surgery for up to 18 weeks from diagnosis

Agreement

If surgery is not possible within 12 weeks, use serial monitoring and only
consider surgery if the tumour progresses clinically significantly

Strong agreement

If surgery is not possible within 12 weeks, do not treat with radioactive iodine or Strong agreement
radiotherapy or palliative treatment as the primary treatment option
Surgery delay
Use serial monitoring to assess tumour progression while waiting

Strong agreement

Promptly re-evaluate treatment options if any evidence of tumour progression

Strong agreement

consider surgery if the tumour progresses. There
was also strong consensus against treating with radio
active iodine or radiotherapy (96·8%), or considering
palliative treatment (100·0%) as the primary treatment
option.
In the case of a T1–T2 differentiated thyroid cancer of
less than 4 cm, there was strong agreement (82·5%) that
nodules directly abutting the airway but not invading it
should be considered as an indication to operate within
4 weeks. There was strong agreement that gross extra
thyroidal extension invading strap muscles only (85·0%),
or regional lymph node metastasis (92·5%) were not
indications for expediting surgery within 4 weeks. There
was no agreement (60·0% in support) on a posterior
nodule in the tracheoesophageal groove.

Monitoring during delay to surgery
When surgery is delayed because of system constraints,
there was strong agreement (92·5%) to use serial
monitoring to assess tumour progression while waiting
for definitive treatment, and any evidence of tumour
progression should prompt re-evaluation of treatment
options or reprioritisation (100·0%).

Actions to optimise resources and reduce risk to patients and staff
Only experienced surgeons should operate on patients

Strong agreement

Avoid a tracheostomy in an oropharyngeal cancer undergoing transoral surgery

Strong agreement

Do not avoid primary free flap reconstruction in favour of delayed
reconstruction at a later date

Strong agreement

Avoid primary free flap reconstruction and instead do local or pedicled flap, if
appropriate

Agreement

Do not avoid neck dissection or sentinel node biopsy in a radiologically N0 neck
cancer at risk of occult metastasis in a T1–T2 or T3–T4 oral or oropharyngeal
cancer

Strong agreement

Do not avoid salvage surgery

Strong agreement

Do not avoid a tracheostomy in an advanced T2–T3 oral cancer requiring free
flap

Agreement

Palliative care as primary treatment in severly constrained settings
Offer primary palliation to patients with poor functional status (eg, spends
>50% of the day in bed or Eastern Cooperative Oncology Group performance
status 3) who have advanced disease

Strong agreement

Offer primary palliation to patients with advanced biological age (eg, >85 years)
who have advanced stage disease

Strong agreement

PPE=personal protective equipment. Strong agreement indicates a threshold of 80% and above. Agreement indicates
a threshold of 67% and above after the third round for statements not considered to have reached a strong agreement.

Table 1: Consensus recommendations for clinical procedures and treatment protocols in a setting of
acute severe resource constraint resulting from the COVID-19 pandemic

(Prof R P Takes PhD);
Department of Clinical
Oncology, The Christie National
Health Service Foundation
Trust, Manchester, UK
(D J Thomson MD); Division of
Cancer Sciences, University of
Manchester, Manchester, UK
(D J Thomson); Division of
Otolaryngology–Head and
Neck Surgery, Dana-Farber and
Brigham and Women’s Cancer
Center, Harvard Medical
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critical airway compression, and no imminent risk to or
involvement of the recurrent laryngeal nerve), there
was strong agreement (82·5%) that it was acceptable to
delay surgery for up to 12 weeks from diagnosis. There
was agreement that delaying surgery for up to 18 weeks
(70·0%) or more (77·5%) is not appropriate. There was
also agreement (77·5%) against delaying surgery
indefinitely, with serial monitoring until progression.
However, if surgery was not anticipated to occur within
the acceptable timeframe, then there was strong
consensus (96·8%) to use serial monitoring and only

Actions to optimise resources and reduce risk to patients and
staff
Experts were asked about the acceptability of avoiding
particular surgical procedures during a time of system
constraints to optimise available resources (eg, to release
bed resources, to decrease PPE use, to decrease operative
time use) and to reduce the risk to patients and staff of
nosocomial transmission of SARS-CoV-2.
There was strong agreement that only experienced
senior surgeons should operate on patients (80·0%)
and that a tracheostomy should be avoided in a patient
with oro
pharyngeal cancer undergoing transoral
surgery (87·5%). There was agreement to accept less
monitoring after surgery (eg, no intensive care bed
or step-down unit) than would usually be used for such
a case (65·0%), and to avoid primary free flap recon
struction and instead use local or pedicled flap recon
struction (72·5%).
There was strong agreement that the following would
not be appropriate: avoiding primary free flap recon
struction and instead operating delayed reconstruction at
a later date (80·0%); avoiding salvage surgery (87·5%);
and avoiding neck dissection or sentinel node biopsy in a
radiologically N0 neck at risk of occult metastasis in a
T1–T2 (85·0%) and T3–T4 (92·5%) oral or oropharyngeal
cancer. There was agreement to not avoid a tracheostomy
in an advanced T2–T3 oral cancer requiring free flap
(67·5%).
There was no agreement on doing a sentinel node
biopsy instead of elective neck dissection for T1–T2 oral
cancer or melanoma (45·0%) or avoiding a neck dis
section or sentinel node biopsy in a radiologically N0 neck
in a case of cutaneous melanoma (35·0%).
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Palliative care as primary treatment
There was no consensus on whether indications for
palliative care as the primary treatment should be
changed in severely constrained settings (47·5%). There
was strong consensus that patients with poor functional
status (eg, patients who spend >50% of the day in bed or
have a Eastern Cooperative Oncology Group performance
status of 3 [82·5%]) and individuals with advanced
biological age (>85 years) who have advanced-stage
disease (92·5%) should also be offered palliative care.
There was no consensus (60·0%) with respect to offering
palliative care for patients who have a low cure rate
(<20% 5-year survival).

Prioritisation in the context of severely constrained
resources
Experts were asked to rank a group of representative
surgical cases in order of priority for time to surgery.
Ranking of the cases was the same in the first and second
rounds, with the top five choices receiving higher mean
priority ranking in the second round than in the first
round (table 2).
Factors that participants considered to be the most
important when prioritising patients in the setting of
constrained resources can be found in panel 2. The order
of selections did not change in the second round.

Discussion
These recommendations, the result of a global consensus
process, aim to provide urgent guidance to frontline head
and neck cancer surgeons who are overworked and
stressed by the COVID-19 pandemic. Endorsed by
39 national and international organisations spanning the
globe, these recommendations should be interpreted and
implemented in the context of national frameworks and
local circumstances, which vary from region to region
and from hospital to hospital, and can change rapidly.
Additionally, these guidelines should be implemented
with multidisciplinary discussion and consider individual
patients’ informed wishes. We have purposefully incor
porated flexibility in the recommendations to enable its
adaptation to the different stages of the pandemic,
including the recovery phase, during which capacity
might be constrained to varying degrees for many
months to come. Importantly, these are recom
men
dations for times of acute and severe resource limitation,
such as the COVID-19 pandemic and natural disasters,
and should not be continued when circumstances return
to a typical state.
In settings with severe resource limitations, reduced
surgical and perioperative care capacities often lead to a
delay in the time to surgery. Therefore, new methods of
service delivery are needed to address these challenges,
which has been acknowledged by the experts in their
recommendations for acceptable delay to surgery. For
early head and neck cancer and low-risk thyroid cancer,
when surgery is likely to be considerably delayed, serial
www.thelancet.com/oncology Vol 21 July 2020

Average
Average
aggregated scores aggregated scores
(Round 2)
(Round 1)

Head and neck surgical scenarios

1

10·5

11·7

T3 N2 oral cancer

2

10·0

10·9

T4 N1 laryngeal cancer

3

8·8

9·8

T4 N0 maxillary cancer

4

8·0

8·7

T4a N1 papillary thyroid cancer with tracheal
invasion

5

7·9

8·0

T3 N1 carcinoma ex-pleomorphic parotid cancer

6

6·9

6·9

T1 or T2 N0 oral cancer

7

6·7

6·1

T2 N1 oropharyngeal cancer p16-negative

8

4·6

4·8

T2 N1 oropharyngeal cancer p16-positive

9

4·2

3·8

T0 N1 unknown primary

10

4·1

3·5

T2 N0 adenoid cystic oral cavity

11

3·4

2·4

T1 N0 laryngeal cancer

12

3·1

1·4

T2 N0 papillary thyroid cancer with a posterior nodule

Head and neck surgical scenarios are ranked in order of priority, from highest to lowest. Rankings did not change
between the first round and second round, so the question was not asked again in the third round.

Table 2: Prioritisation of surgery by ranking for patients with head and neck cancer in a setting of acute
severe resource constraint

Panel 2: Top five factors for the prioritisation of surgery in
patients with head and neck cancer in a setting of acute
severe resource constraint
• Chance of tumour progression with delay (risk to patient)
• COVID-19 status of patient (risk to patient, other patients,
and staff)
• Prognosis (risk to patient)
• Availability of infrastructure to operate on patients with
COVID-19, including personal protective equipment and
trained staff (risk to patients and staff)
• Effectiveness and availability of alternative treatments
(risk to patient)
Factors are listed in order of considered importance, from
most commonly selected to least commonly selected.

monitoring might be a viable alternative with intervention
only on progression. Consideration of non-surgical
treatments is another alternative, but this option depends
on the type of cancer and is much more acceptable for
early cancer of the larynx than for other head and neck
subsites. With serial monitoring, it is important to ensure
that it is sufficiently frequent and in a format that allows
early identification of progression. If these conditions are
not possible because of resource limitation, then
alternative treatment options should be explored instead.
The situation is different when considering advanced
head and neck cancer. Delay or serial monitoring was
considered far less acceptable than in the case of early
head and neck cancer. In this setting, early consideration
of alternative treatments, such as radiotherapy or
chemoradiotherapy, should be considered when optimal
primary surgery cannot be delivered in acceptable
timeframes.
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For more on the HNCIG see
www.hncig.org
See Online for appendix

Search strategy and selection criteria
To identify areas of uncertainty in clinical practice caused by
acute resource constraint and the COVID-19 pandemic, we
did a literature search of PubMED, Embase, Medline, and
Google that included grey literature, individual association
correspondence, and guidelines on COVID-19 and head and
neck cancer. We used the main search terms ‘head neck
cancer’ and ‘COVID-19’ and searched for articles published
between Nov 1, 2019, to April 1, 2020. We limited our
search to papers published in English and prioritised peerreviewed papers, large series papers, and guidelines
published by national or international bodies. Discussions
with HNCIG board members highlighted areas of
uncertainty identified in the literature, along with
challenges to clinical practice. All issues were then collated
into initial domains and questions formulated by the
multidisciplinary steering group. All questions were piloted
by three independent experts (SVP, VP, CS) for readability,
as well as face and content validity,. Survey questions and
the results of all three rounds are provided in the
appendix (pp 2–5).

Experts strongly agreed on the need to protect staff
and patients from SARS-CoV-2 exposure. The state
ments reflect this agreement in their recommendations
to use flexible nasendoscopy only in patients who are
deemed to be at high risk and, even then, only when
adequate PPE is available. Experts also supported new
modalities of follow-up, favouring remote (eg, tele
health) consultations where possible, with face-to-face
follow-up reserved for patients with concerning symp
toms. Cessation of consultations altogether was not
considered acceptable.
The COVID-19 pandemic has severely strained typical
doctor–patient relationships.29 Clinicians are used to
the act of prioritisation as resources are not infinite.
However, the extent and scale to which this prioriti
sation has been necessary during the pandemic is
unprecedented for most practitioners. The resultant
considerable uncertainty and ethical concerns about
the implications for patients in terms of stage migration,
or worse, pose the risk of so-called moral injury to
clinicians.30 These recommendations might help to
reduce uncertainty in care, decrease inconsistencies,
and provide reassurance as to what is acceptable to most
experts in the field, thus reducing the risks of stress and
moral injury.
These recommendations have limitations. They address
what we believe are the most important issues for head
and neck surgeons in a setting of severely constrained
resources, but they cannot cover every eventuality,
especially as the nature of the pandemic changes from
acute to endemic. Therefore, clinical networks are needed
(locally, nationally, and internationally) to help to provide
ongoing support to frontline clinicians and to address
e357

difficult issues as they arise. The HNCIG, with its global
reach and network of partners established during this
consensus process, is considering ways of addressing this
need moving forward.
The original Delphi process allowed participants to
change their past responses after being presented with
the results of the previous round.28 In view of the
urgency and to simplify and speed up the process, we
presented participants with the results of the previous
round, then invited them to change their responses in
the next round, because there were only 2 days between
each round. The proportions of agreement that are
reported within the body of the recommendations are
those that were reached at the point of first consensus.
An agreement of 85% at the first round might have
improved to 95% in the second or third round, but
reaching the highest degree of consensus is not the
purpose of this process. Therefore, the rates of strong
agreement that are reported should not be directly
compared with each other, as they might have been
reached at different rounds.
Agreement is always a reflection of the participants
and their backgrounds. In this process, most of the
participants were surgeons as these were recom
mendations for surgical practice and this should be
taken into account when considering this statement.
Recommen
dations for head and neck cancer radio
therapy during the COVID-19 pandemic have recently
been published by the American Society for Therapeutic
Radiology and Oncology and the European Society for
Radiotherapy and Oncology.13 These recommendations
also used an online modified Delphi process, which we
used when designing our method. Taken together,
these two statements will hopefully provide multi
disciplinary services for head and neck oncology with
comprehensive recommendations for practice during
the COVID-19 pandemic.

Conclusion
Sadly, this pandemic is not likely to be the last disaster
faced by our global community. Although these recom
mendations for head and neck surgical practice have
been developed during the COVID-19 pandemic, we
believe that the methods used and the context of the
questions posed means that they could be used in other
settings of acute and severely constrained resources, as
well as in settings with a high risk of injury to patients
and staff. These environments could include epidemics
and other natural disasters, such as large-scale flooding
or earthquakes. Furthermore, we believe that the
methods used to develop these recommendations, the
speed with which they were developed, and the scale of
cooperation and collaboration between the international
and national bodies involved is a strong example of how
global collaboration can help to address urgent challenges
facing clinicians in times of acute stress and disaster. We
plan to publish the detailed methods and provide
www.thelancet.com/oncology Vol 21 July 2020
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open-access templates on the HNCIG website, so that
they can be easily applied should the need arise again in
the future.
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